'Novel' Therapies such as Sarizotan and Safinamide are Expected to Make Little Impact by 2009 because of their Lack of True Novelty Compared with Existing Parkinsons Disease Therapies.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c32164) has announced the addition of Parkinsons Disease Presents Lucrative Market Opportunities to their offering Parkinson's disease Parkinson's disease or Parkinsonism, degenerative brain disorder first described by the English surgeon James Parkinson in 1817. When there is no known cause, the disease usually appears after age 40 and is referred to as Parkinson's disease. (PD) is an attractive target for drug development because of the chronic, progressive nature of the disease and the fact that no currently available treatments slow or stop the disease's progression. Moreover, an ever-growing elderly population will lead to a steadily increasing number of PD sufferers over the next several decades; this fact makes the PD market a highly lucrative area of opportunity for drug developers with novel strategies that might address critical areas of unmet need. In this Decision Resources report, an overview of the disease is provided, key players in the PD market are profiled, new agents are discussed that are projected to enter the market during the 2005-2009 period, and the market outlook for PD through 2009 is detailed. Business Implications - Parkinson's disease (PD) is an attractive drug development target because it is a chronic, progressive disease and because no treatments are currently available that can slow or stop its progression. - Few key players compete in the PD market because levodopa levodopa: see l-dopa. levodopa or L-dopa Organic compound (L-3,4-dihydroxyphenylalanine) from which the body makes dopamine, a neurotransmitter deficient in persons with parkinsonism. , which has been marketed for more than 40 years, remains the gold standard for treating PD and because developing successful PD drugs requires considerable expertise and significant investment in lengthy clinical trials. Major players include Boehringer Ingelheim, Pfizer, GlaxoSmithKline, and Novartis. - Dopamine agonists A dopamine agonist is a compound that activates dopamine receptors, mimicking the effect of the neurotransmitter dopamine. Uses Some medical drugs act as dopamine agonists; they are typically used for treating Parkinson's disease, and may be useful for restless legs , the leading drug class on the PD market, are used as adjunct adjunct (aj´ungkt), n a drug or other substance that serves a supplemental purpose in therapy. adjunct therapy for patients taking levodopa and as early therapy to delay the need for levodopa, which is associated with serious complications. It is projected that dopamine agonists will continue to drive the PD market through 2009. - Despite considerable R&D activity in the PD arena, few new drugs have reached this market in recent years. One main reason is the high failure rate in advanced clinical trials. Five high-profile drugs have been discontinued dis·con·tin·ue v. dis·con·tin·ued, dis·con·tin·u·ing, dis·con·tin·ues v.tr. 1. To stop doing or providing (something); end or abandon: in the past several years. "Novel" therapies such as sarizotan and safinamide are expected to make little impact by 2009 because of their lack of true novelty compared with existing PD therapies, their projected slow uptake, and their likely relegation RELEGATION, civil law. Among the Romans relegation was a banishment to a certain place, and consequently was an interdiction of all places except the one designated. 2. It differed from deportation. (q.v.) Relegation and deportation agree u these particulars: 1. to use primarily as adjunctive therapy adjunctive therapy Medtalk A therapeutic maneuver(s) with an ancillary role in treating a disease by ↓ M&M, but not part of the immediate therapy required to stabilize the Pt. Cf Adjuvant therapy. . - Key drivers of growth in the PD market will include increasing use of polytherapy with expensive PD drugs in place of levodopa and a steadily growing PD population as general populations in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. , Europe, and Japan age. Key topics covered in this report include: - An Attractive Target - Overview - Key Players and Current Therapies - New Market Entrants Through 2009 - Teva/Lundbeck/Eisai's Rasagiline (Agilect) - Schwarz Pharma's Rotigotine CDS - GlaxoSmithKline's Ropinirole ropinirole /ro·pin·i·role/ (ro-pin´i-rol?) a dopamine agonist used as the hydrochloride salt as an antidyskinetic in the treatment of Parkinson's disease. ro·pin·i·role n. OCR OCR in full optical character recognition Scanning and comparison technique intended to identify printed text or numerical data. It avoids the need to retype already printed material for data entry. - Kyowa Hakko Kogyo's Istradefylline - Safinamide - Sarizotan - Market Outlook Through 2009 Companies mentioned in this report include: - Boehringer Ingelheim - Eisai - GlaxoSmithKline - Kyowa Hakko Kogyo - Lundbeck - Novartis - Pfizer - Schwarz Pharma - Teva For more information visit http://www.researchandmarkets.com/reports/c32164 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion